Ainos, Inc.
Ainos, Inc. (AIMDW) Stock Overview
Explore Ainos, Inc.’s financial performance, market position, analyst ratings, and future outlook.
AIMDW Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ainos, Inc. (AIMDW) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.54 and a market capitalization of 12.8M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.
Chun-Hsien Tsai
44
8880 Rio San Diego Drive, San Diego, TX
1970